cpass test Search Results


90
GenScript corporation cpass surrogate virus neutralization test (svnt)
Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the <t>cPass™</t> ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).
Cpass Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass surrogate virus neutralization test (svnt)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass surrogate virus neutralization test (svnt) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass test
Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the <t>cPass™</t> ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).
Cpass Test, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass test/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Medac GmbH elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass
(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) <t>SARS-CoV-2</t> S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.
Elisa Based Sars Cov 2 Rbd Ace2 Binding Inhibition Assay (Surrogate Sars Cov 2 Neutralization Test (Svnt) Cpass, supplied by Medac GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass/product/Medac GmbH
Average 90 stars, based on 1 article reviews
elisa-based sars-cov-2 rbd-ace2 binding inhibition assay (surrogate sars-cov-2 neutralization test (svnt) cpass - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpass (qualitative test)
(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) <t>SARS-CoV-2</t> S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.
Cpass (Qualitative Test), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass (qualitative test)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass (qualitative test) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the cPass™ ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the cPass™ ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Binding Assay, Activity Assay, Vaccines, Inhibition, Enzyme-linked Immunosorbent Assay

Neutralizing activity evaluated by cPass™ ELISA-based SARS-CoV-2 Neutralization Antibody Detection Kit in 70 sera from differently vaccinated individuals. Serum samples were considered positive when ≥30% inhibition was measured, as shown by the red line in the graph. (A) Percentage inhibition of receptor-binding domain–angiotensin-converting enzyme 2 (RBD-ACE2) binding within different vaccination groups (see also <xref ref-type= Table 3 ). Statistical significance was assessed by ANOVA following Tukey’s multiple comparisons test, ** p < 0.005, * p < 0.05. (B) Comparison of neutralizing activity in sera from individuals who received adenoviral DNA-based vaccines and mRNA-based vaccines. Statistical significance was assessed by unpaired t-test, * p = 0.0016. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Neutralizing activity evaluated by cPass™ ELISA-based SARS-CoV-2 Neutralization Antibody Detection Kit in 70 sera from differently vaccinated individuals. Serum samples were considered positive when ≥30% inhibition was measured, as shown by the red line in the graph. (A) Percentage inhibition of receptor-binding domain–angiotensin-converting enzyme 2 (RBD-ACE2) binding within different vaccination groups (see also Table 3 ). Statistical significance was assessed by ANOVA following Tukey’s multiple comparisons test, ** p < 0.005, * p < 0.05. (B) Comparison of neutralizing activity in sera from individuals who received adenoviral DNA-based vaccines and mRNA-based vaccines. Statistical significance was assessed by unpaired t-test, * p = 0.0016.

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Neutralization, Inhibition, Binding Assay, Comparison, Vaccines

Mean neutralizing activity measured by the  cPass™  ELISA-based assay in sera from 70 individuals who received different vaccines.

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Mean neutralizing activity measured by the cPass™ ELISA-based assay in sera from 70 individuals who received different vaccines.

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Vaccines

(A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Microarray, Neutralization, MANN-WHITNEY, Inhibition, Release Assay

( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: ( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Inhibition